Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 263Genitourinary 163Breast 156Tumor-Agnostic 135Thoracic 95Dermatologic 68Head & Neck 58CNS 57Sarcoma 51Gynecologic 44Endocrine 29NET 10Lymphoid 6Other hematologic neoplasm 4Myeloid 4Other solid neoplasm 3Classical hematology 3Plasma cell 2Other 1

Conditions

Anemia, Refractory, with Excess of Blasts 115Myelodysplastic Syndromes 107Leukemia 98Leukemia, Myeloid, Acute 92Anemia 70Leukemia, Myelomonocytic, Chronic 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Myeloproliferative Disorders 55Leukemia, Lymphocytic, Chronic, B-Cell 52Multiple Myeloma 48Anemia, Refractory 48Thrombocytopenia 45Lymphoma 43Lymphoma, Non-Hodgkin 42Neoplasms 40Hodgkin Disease 39Primary Myelofibrosis 36Leukemia, Myeloid, Chronic-Phase 36Congenital Abnormalities 34Anemia, Aplastic 34Myelodysplastic-Myeloproliferative Diseases 33Leukemia, Myelogenous, Chronic, BCR-ABL Positive 33Leukemia, Myeloid, Accelerated Phase 32Lymphoma, Follicular 29Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 26Burkitt Lymphoma 25Lymphoma, Mantle-Cell 24Neoplasms, Plasma Cell 23Lymphoma, B-Cell, Marginal Zone 23

Interventions

sargramostim 1fludarabine phosphate 1fludarabine 1Rosuvastatin Calcium 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cyclosporine 1Cyclophosphamide 1Alemtuzumab 1ACE-011 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Classical hematology × Clear all
NCT00931606 2023-09-13

MK-7962-012

Merck Sharp & Dohme LLC

Phase 2 Terminated
30 enrolled 32 charts
Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

NCT01524653 2018-07-10

DISOLVE

University of Vermont

Phase 2 Completed
38 enrolled
Classical hematology

Neoplasm Metastasis, Neoplasms, Venous Thrombosis, Venous Thromboembolism

NCT00533923 2016-07-18

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Beth Israel Deaconess Medical Center

Phase 2 Completed
25 enrolled
Classical hematologyLymphoidMyeloidPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡